No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Small-cap biotech valuation asymmetry after bear market
The macro-driven five-year bear market in biotech has created a highly asymmetric risk-reward setup in small-cap companies trading at low enterprise values.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.